Represents of disclosure of notes to the consolidated financial statements.

No definition available.

Name:	cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems
Namespace Prefix:	cvac_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of upfront payments of the company included in contract liabilities.

+ References

No definition available.

+ Details

Name:	cvac_UpfrontPaymentsIncludedInContractLiabilities
Namespace Prefix:	cvac_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of upfront payments received or receivable by the company.

+ References

No definition available.

+ Details

Name:	cvac_UpfrontPaymentsReceivedOrReceivable
Namespace Prefix:	cvac_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The amount of revenue that was included in the contract liability balance at the beginning of the period. [Refer: Contract liabilities; Revenue from contracts with customers]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 15
-IssueDate 2022-03-24
-Paragraph 116
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_116_b&doctype=Standard
-URIDate 2022-03-24

+ Details

Name:	ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	ifrs-full_MajorCustomersAxis=cvac_GlaxosmithklineMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_MajorCustomersAxis=cvac_CrisprMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_MajorCustomersAxis=cvac_GenmabMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_ProductsAndServicesAxis=cvac_ResearchServicesCombinedWithIpLicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Notes to the Consolidated Statements of Operations - Summary of upfront payments and related revenues recognized (Details) € in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023 EUR (€)	Jun. 30, 2022 EUR (€)	Jun. 30, 2023 EUR (€)	Jun. 30, 2022 EUR (€)	Jun. 30, 2023 USD ($)	Dec. 31, 2022 EUR (€)
Notes to the Consolidated Statements of Operations
Upfront and milestones payments included in contract liabilities	€ 98,763		€ 98,763			€ 107,308
GSK
Notes to the Consolidated Statements of Operations
Upfront and milestone payments	205,000		205,000
Upfront and milestones payments included in contract liabilities	95,307		95,307			102,804
CRISPR
Notes to the Consolidated Statements of Operations
Upfront and milestone payments	2,524		2,524		$ 3,000
Upfront and milestones payments included in contract liabilities	775		775			929
Genmab
Notes to the Consolidated Statements of Operations
Upfront and milestone payments	8,937		8,937		$ 10,000
Upfront and milestones payments included in contract liabilities	2,681		2,681			€ 3,575
Minimum \| GSK
Notes to the Consolidated Statements of Operations
Upfront and milestone payments	10,000		10,000
Research services combined with an IP license
Notes to the Consolidated Statements of Operations
Revenue recognized from upfront and milestones payments	4,397	€ 13,575	8,545	€ 31,818
Research services combined with an IP license \| GSK
Notes to the Consolidated Statements of Operations
Revenue recognized from upfront and milestones payments	3,873	13,051	7,496	30,769
Research services combined with an IP license \| CRISPR
Notes to the Consolidated Statements of Operations
Revenue recognized from upfront and milestones payments	77	77	155	155
Research services combined with an IP license \| Genmab
Notes to the Consolidated Statements of Operations
Revenue recognized from upfront and milestones payments	€ 447	€ 447	€ 894	€ 894